The initiative introduces the “Green Medical Pass,” which offers priority access to more than 2,000 healthcare providers, including over 500 doctors and 30 specialties, across both jurisdictions.
The service aims to address growing healthcare access challenges in Hong Kong, where waiting times for specialist outpatient services have reached new highs, with some exceeding two years, according to recent data from the Hospital Authority.
As healthcare infrastructure in Mainland China continues to expand, cross-border access to medical services has become more relevant for Hong Kong-based patients.
In 2023, the Shenzhen Health Commission recorded over 700,000 medical consultations provided to Hong Kong residents.
AXA’s chief life and health insurance officer, Janet Lee, noted that increasing integration between Hong Kong and Mainland cities has led to rising interest in cross-border medical services.
“After the pandemic, cross-border interactions between Hong Kong and Mainland China have become increasingly frequent, with growing number of Hong Kong residents seeking medical services in the Mainland,” she said.
She said the offering is designed to connect customers with a broader range of healthcare resources across the region, supporting timely intervention and continuity of care.
“This provides customers with more diverse and precise healthcare options, facilitating earlier intervention, reducing suffering, and improving medical outcomes. We believe true protection goes beyond post-treatment claims – it covers proactive prevention, timely treatment, and comprehensive post-recovery support throughout the entire healthcare journey,” Lee said.
The new service includes three main components:
These offerings build on AXA’s previous concierge platforms tailored for cancer and endoscopy treatment, particularly those focused on the Greater Bay Area’s cross-border care network.
Separately, AXA China Region Insurance Company (Bermuda) Limited and AXA International Reinsurance (Shanghai) Company Limited have signed a Memorandum of Understanding with China Biotech Services Holdings Limited.
The agreement will support research and development in cancer treatment, with particular focus on Boron Neutron Capture Therapy (BNCT).
BNCT is a radiotherapy technique involving the administration of a boron compound followed by neutron irradiation. This process causes a nuclear reaction that targets cancerous cells while limiting exposure to healthy tissue.
The method is currently being explored for patients with brain tumours, recurrent head and neck cancers, and other hard-to-treat malignancies. Ongoing trials are also examining its use in liver cancer, melanoma, and mesothelioma.
AXA’s broader healthcare strategy continues to focus on expanding treatment access across borders.
Recent updates to its concierge networks include enhanced cancer care coverage, the introduction of an endoscopy service, and new benefits such as recovery subsidies and premium waivers for eligible medical insurance and employee benefits policyholders.
